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ABSTRACT
The study of eukaryotic initiation factor 4E (eIF4E) is a key focus in cancer 
research due to its role in controlling the translation of tumour-associated proteins, 
that drive an aggressive migratory phenotype. eIF4E is a limiting component of the 
eIF4F complex which is a critical determinant for the translation of mRNAs. Mitogen-
activated protein kinase interacting protein kinases (MNK1/2) phosphorylate eIF4E 
on Ser209, promoting the expression of oncogenic proteins, whereas mTORC1 
phosphorylates and de-activates the eIF4E inhibitor, 4E-BP1, to release translational 
repression. Here we show that inhibiting these pathways simultaneously effectively 
slows the rate of cell migration in breast cancer cells. However, a molecular 
hybridisation approach using novel, cleavable dual MNK1/2 and PI3K/mTOR inhibiting 
hybrid agents was less effective at slowing cell migration.
www.impactjournals.com/oncotarget/ Oncotarget, Advance Publications 2018
INTRODUCTION
Metastasis of cancer cells and the formation of 
malignant secondary tumours is extremely problematic in 
the clinic, accounting for approximately 90% of human 
cancer deaths [1]. Cancer cells require elevated protein 
synthesis to invoke this invasive phenotype, which has 
the ability to bypass tissue barriers, intravasate into the 
bloodstream and seed at distal secondary sites [2]. This 
is particularly apparent in Triple-Negative Breast Cancer 
(TNBC), a rapidly spreading, primary breast cancer that 
has poor prognosis and limited treatment options [3].
MAPK-interacting kinases (MNKs) are serine/ 
threonine kinases that lie downstream of essential 
signaling pathways, and are commonly amplified in 
cancer cells [4]. Each MNK gene, MKNK1 and MKNK2, 
produces a long and a short isoform through variation in 
splicing [5, 6]. The longer isoforms (MNK1a and MNK2a) 
contain a MAPK binding site, which is lacking in the 
shorter isoforms (MNK1b and MNK2b) [5, 6]. The MNKs 
differ in their regulation; MNK1a has low basal activity, 
and is activated and tightly regulated by ERK and p38 
kinases in response to mitogens and stress [7, 8]. MNK2 
displays high basal activity and is predominantly regulated 
by ERK1/2, although MNK2a is regulated by mTORC1 
through at least one site in its C-terminal region [9, 10].  
The eukaryotic translation initiation factor 4E 
(eIF4E) is the rate-limiting component of the eIF4F 
complex, essential for cap-dependent translation. Its 
availability is regulated by mTORC1, through the 
phosphorylation of 4E-binding protein 1 (4E-BP1). 
MNK1/2 phosphorylate S209 of eIF4E, promoting 
the expression of oncogenic proteins. Phosphorylated 
eIF4E (eIF4E-P) preferentially enhances the translation 
of a subset of mRNAs involved in cell survival. These 
include a number of genes implicated in metastatic and 
invasive behaviour, such as C-MYC, cyclin D1, PIM-
1, survivin, BCL-2, vascular endothelial growth factor 
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(VEGF), fibroblast growth factor (FGF-2) and matrix 
metalloproteinase-9 (MMP9) [11, 12]. This addiction to 
increased protein synthesis provides a therapeutic window 
to selectively target the translational machinery of cancer 
cells [13, 14]. 
MNK1/2 represent an attractive potential therapeutic 
target as they act at the convergence point of two critical 
signaling pathways; p38MAPK and ERK, which are 
often subject to up-regulation in tumour cells [4, 15–17]. 
MNK1/2 knockout mice exhibit total abrogation of 
eIF4E phosphorylation and display no developmental 
or reproductive defects [15, 18].  Furthermore, knock-in 
mice expressing a mutant form of eIF4E (S209A) are no 
longer phosphorylated on eIF4E by MNK1/2 and exhibit 
resistance to neoplastic transformation [19]. 
There is evidence for a compensatory feedback 
mechanism linking the PI3K-AKT-mTOR and the MNK-
eIF4E pathways. In prostate and lung cancer, down-
regulation of one pathway correlated with the activation 
of the other, which subsequently promoted cell growth 
and cancer survival [18, 20]. Dual inhibition of MNK1/2 
kinase and mTORC1 suppressed cell cycle progression 
and blocked proliferation in both prostate and glioblastoma 
cell lines. This effect was increasingly pronounced when 
inhibitors were added in combination, indicating the 
importance of dual abrogation of such pathways [18, 20]. 
Recently published work also found that increased levels 
of eIF4E-P was a common feature in breast cancer patient 
response to chemotherapy and was associated with poor 
clinical outcome. Treatment with MNK1/2 inhibitors 
sensitised breast cancer cells to chemotherapy in vivo and 
resulted in an enhanced response to treatment [21].
The heterogeneous nature of cancer and complexity 
of cellular signalling means that the traditional single 
treatment approach is often ineffective. Inhibition of 
multiple targets is required to outsmart the tumour cell [13, 
22, 23]. This has led to the concept of hybrid drugs, which 
involves the linking of two selected pharmacophores 
that act against different therapeutic intracellular targets 
simultaneously. This multi-hit approach may lead to an 
increase in synergy and make drug resistance less likely 
to occur [18]. 
There are no FDA approved drugs that specifically 
act on MNK1/2. The pyrazolo-pyrimidine compound 
CGP57380 exhibits low micromolar MNK1 inhibition and 
cercosporamide, a natural anti-fungal agent, was found to 
be a potent inhibitor of MNK1/2 [4, 7, 9, 11, 14, 15, 17]. 
However, the broad spectrum effects of cercosporamide 
limit its uses as an effective treatment [4, 24, 25]. Due 
to our interest in developing a hybrid therapy we sought 
to identify a MNK1/2 inhibitor with the characteristics 
to facilitate the development of such agents. A potent 
MNK1/2 inhibitor, 1, has recently been synthesised, which 
is relatively selective compare with current inhibitors [26]. 
In this study, we examined the effect of dual 
inhibition of MNK-eIF4E and PI3K-AKT-mTOR 
pathways (Figure 1) on cell migration, cell viability 
and cell cycle arrest. These data led to the attempted 
development of dual action MNK hybrid agents, with a 
view to simultaneously inhibit these pathways.
RESULTS AND DISCUSSION
The effect of dual-inhibition of both eIF4E-MNK 
and PI3K-AKT-mTOR pathways on downstream 
signalling molecules in MRC5 cells
MNK1/2 phosphorylate eIF4E on S209, enhancing 
the translation of specific mRNAs involved in cell 
survival and metastasis. MNK1/2 kinases are an attractive 
therapeutic target as they are dispensable during normal 
development and hence could be used to selectively kill 
cancer cells [26]. In our study, highly migratory MRC5 
lung fibroblasts and MDA-MB-231 breast cancer cells 
(wildtype PI3K and BRCA1, mutated KRas (G13D) 
[28] and mutated P53 (missense mutation) [29]) were 
both used to probe the response of dual-inhibition of the 
eIF4E-MNK pathway and PI3K-AKT-mTOR pathways 
(Figure 1). Compound 1 (Figure 2), was found to be a 
potent MNK1/2 inhibitor in the nanomolar range in 
cell-free kinase assays [30].  In our hands, Compound 
1 reduced the level of eIF4E phosphorylation in a 
concentration-and time-dependent manner, being effective 
at concentrations above 1 µM for 4 hours or longer (Figure 
3A and 3B). In contrast, CGP57380 (Figure 3A, lane 8) 
and staurosporine (Figure 3A, lane 9) had no effect on 
eIF4E-P under these assay conditions. The inhibition 
of MNK1/2 did not affect the upstream activation of 
MNK1/2, or lead to an increase in cell stress, as observed 
by the constant level of AMPK T172 phosphorylation in 
relation to the DMSO control. Increased incubation time 
with 1 for 16 hours and above, resulted in partial inhibition 
of 4E-BP1 phosphorylation, as depicted by an increase in 
the level of the less-phosphorylated form of 4E-BP1 upon 
Western blotting (Figure 3A and 3B). 
To assess the significance of simultaneous MNK1/2 
and PI3K inhibition, an effective PI3K p110α inhibitor, 
3-[4-(4-morpholinyl)thieno[pyrimidin-2-yl]phenol, 2, 
[31], was used to observe the effect on various signalling 
molecules (Figure 2 and Figure 3C). The efficacy of 2 as a 
PI3K inhibitor was measured by monitoring the inhibition 
of phosphorylation of AKT-T308. This phosphorylation 
is PI3K-dependent, resulting from the conversion of 
PIP2 to PIP3 and the activation of PDK1 [32]. Molecule 
2 was found to inhibit AKT-T308 phosphorylation at 
concentrations greater than 100 nM in MRC5 cells. The 
observed effect of 2 on mTOR signalling was also as 
predicted, with mTORC1 substrates, 4E-BP1, p70S6K 
and consequently ribosomal protein S6 phosphorylation 
inhibited in a dose-dependent manner (Figure 3C). This 
is explained by the shared sequence similarity in the 
C-terminal kinase domain of both mTOR and PI3K [33]. 
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Interestingly, 2 appeared to reduce the level of eIF4E-P at 
high concentrations, suggesting an overlapping function in 
the eIF4E-MNK pathway. The phosphorylation of eIF4E 
was abolished when 2 was used in combination with 1.
When monitored by Western blotting, the level of 
eIF4E protein remained constant throughout the drug-
treated cells. A low level of cleaved PARP was observed 
when 2 was used at high concentrations alone or in 
combination with 1 (Figure 3C), indicating apoptosis at 
elevated final concentrations. 
In addition to targeting the PI3K pathway at 
the level of PI3K, we used the pyrimidine derivative, 
PP242 (torkinib), to inhibit this pathway. PP242 has an 
IC50 of 8 nM in cell-free assays and selectively targets 
both mTORC1 and mTORC2 complexes over PI3K 
isoforms [34] (Figure 1). Consistent with published data 
[34], PP242 at a 1 µM final concentration inhibited the 
phosphorylation of 4E-BP1 (Figure 3D and 3E) as well as 
other targets downstream of mTORC1, including p70S6K 
and ribosomal protein S6 (data not shown). There was a 
Figure 1: A simplified schematic representation of MNK1/ 2 and mTOR pathways. Red boxes depict several inhibitors 
of specific pathway components used in this study. MNK1/2 lie at the convergence point of both the p38MAPK pathway and ERK 
pathways and upon activation, phosphorylate eIF4E. Class I PI3 kinases are activated by RTKs resulting in the conversion of PIP2 to 
PIP3, a secondary messenger that is essential for AKT translocation to the plasma membrane. The level of PIP3 is negatively regulated 
by the tumour suppressor, PTEN. AKT is partially activated by PDK1 and becomes fully activated upon phosphorylation at Ser473, a 
process that can be catalysed by multiple proteins. mTOR forms two distinct multiprotein complexes, mTORC1 and mTORC2. mTORC1 
is activated indirectly through AKT. Activated mTORC1 stimulates protein translation by phosphorylating 4E-BP1 on several residues, 
releasing eIF4E allowing it to participate in translation initiation. In addition to phosphorylating other translational targets, mTORC1 also 
phosphorylates p70S6 kinase (p70S6K), which becomes fully activated following PDK1-mediated phosphorylation.
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low level of cell death in cells exposed to the 1/ PP242 
combination, with more cleaved PARP observed at the 
highest concentration of 1 (10 µM; lane 2). Incubation of 
cells with PP242 at 1 µM concentration in combination 
with various concentrations of 1 did not affect the efficacy 
of the latter on eIF4E-P. The level of ERK-P appeared to 
be unaffected under all of the conditions tested. 
Inhibition of MNK1/2 and the PI3K-AKT-
mTOR pathway slows the rate of migration in 
MDA-MB-231 cells
The phosphorylation of eIF4E correlates with 
an increase in levels of mesenchymal markers such 
as N-cadherin, fibronectin and vimentin, along with 
the acquisition of invasive properties [35]. Disrupting 
cellular migration is a promising therapeutic option for 
the treatment of cancer [36]. Here, we assessed the rate 
of migration of a breast cancer cell line using real-time 
monitoring of cell migration. MDA-MB-231 cells were 
analysed in the presence of various inhibitors alone or in 
combination as they moved towards a chemo-attractant. 
Cell migration kinetics were recorded on a RTCA DP 
instrument for 12 hours. As shown in Figure 4A and 4B, 
when cells were treated with a combination of 1 and 2 
(both at 1 µM final concentration), a substantial reduction 
in cell migration was observed relative to the DMSO 
control. In comparison, when used as single agents, both 
1 and 2 had negligible effects on cell migration. Cell 
viability data demonstrated that the MNK1/2 inhibitor, 1, 
exhibited minimal cytotoxicity at 1 µM in MDA-MB-231 
cells (Figure 4E and 4F). The PI3K inhibitor, 2, reduced 
cell viability to 75%, when used either as a single agent or 
in combination with 1.
The synergistic effect of MNK1/2 and PI3K 
inhibition on cell migration led to the investigation of 
inhibition of both MNK1/2 and mTORC1/2, using PP242. 
The latter, impaired cell migration to the greatest extent 
(Figure 4C), although this could in part be explained by a 
reduction in cell viability to 60% seen with this compound 
(Figure 4F). A combination of 1 with PP242 appeared 
to rescue the effect of PP242 used alone, with the cell 
index returning to the level of the DMSO control (Figure 
4C). One possible explanation for this reflects a recent 
publication demonstrating that MNK forms a complex 
with mTORC1, promoting mTORC1 association with 
TELO2 (Phosphatidyl Inositol 3ʹ Kinase-related Kinase 
(PIKK) stabiliser), which facilitates efficient mTORC1/
substrate binding [37].
The dual inhibition of MNK1/2 and mTORC1/2 
significantly reduced cell viability to 35% on control levels 
(Figure 4F), an observation that has been reproduced 
in several cancer cell lines [18, 20]. The rescue effect 
seen when a combination of MNK1/2 and mTORC1/2 
inhibition was used in the cell migration assay suggests 
only a selected pool of surviving cells were scored in this 
assay.
The combination of MNK1/2 and mTORC1/2 
inhibition induces G1 cell cycle arrest in MDA-
MB-231 cells 
Next, we investigated whether a combination 
of MNK1/2 and PI3K or mTORC1/2 inhibition was 
associated with cell cycle arrest in proliferating MDA-
MB-231 cells over a period of 24 hours. The CDK1 
inhibitor, R0-3306, was used as a control for the arrest 
of cells at the G2/ M phase border [38]. As demonstrated 
in Figure 5, each phase of the cell cycle showed a normal 
Figure 2: Inhibitors. (A) Structure of 1, a MNK1/ 2 inhibitor. (B) Structure of 2, a PI3K p110α inhibitor. (C) Structure of PP242, a 
mTORC1/2 inhibitor. (D) Structure of cercosporamide, a MNK1/2 inhibitor. (E) Structure of CGP57380, a MNK1/2 inhibitor.
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Figure 3: Representative Western blot analysis of both the eIF4E-MNK and PI3K-AKT-mTOR pathways in the 
presence of inhibitors. (A) Western blot analysis showing the effect of different concentrations of 1 on eIF4E-P and various signalling 
molecules. MRC5 fibroblast cells were incubated with DMSO alone (lane 1) or with the indicated concentrations of inhibitors for 24 hours. 
Cellular lysates were prepared and immunoblotting was performed using 20 µg of total lysate protein, as described in the Materials and 
Methods. (B) Western blot analysis showing the effect of 1 incubation time on eIF4E-P and various signalling molecules. MRC5 fibroblast 
cells were incubated with DMSO alone (lane 1) or with 1 (5 μM) for the indicated times. (C) Western blot analysis showing the effect 
of different concentrations of 2 on AKT-308 phosphorylation and various signalling molecules and the effect of 2 in combination with 
1. MRC5 fibroblast cells were incubated with DMSO alone (lane 1) or with the indicated concentrations of inhibitors for 24 hours. (D) 
Western blot analysis showing the effect of different concentrations of PP242 on 4E-BP1 phosphorylation. MRC5 cells were incubated 
with DMSO alone (lane 1) or the following final concentrations of PP242: lane 2: 5 µM, lane 3: 2.5 µM, lane 4: 1 µM, lane 5: 500 nM, lane 
6: 100 nM. (E) Western blot showing the effect of different concentrations of 1 in combination with PP242 1 µM.  Cells were incubated 
with DMSO alone (lane 1) or the following final concentrations of inhibitors: lane 2: 1 10 µM, PP242 1 µM, lane 3: 1 5 µM, PP242 1 µM, 
lane 4: 1 2.5 µM, PP242 1 µM lane 5: 1 1 µM, PP242 1 µM, lane 6: 1 500 nM, PP242 1 µM lane 7: 1 100 nM, PP242 1 µM. 
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distribution in the DMSO control cells. The MNK1/2 
inhibitor, 1, had no effect on cell cycle distribution, 
whereas both mTORC1/2 and PI3K inhibition, (PP242 and 
2, respectively) increased the number of cells in the G1 
phase of the cell cycle. However, following exposure to a 
combination of 1 and PP242 at 5 µM, the number of cells 
corresponding to the G1 phase was increased, while the 
numbers of cells in the S and G2/M phases were decreased. 
This combination of inhibitors had a synergistic effect on 
G1 cell cycle arrest. 
Figure 4: Cell viability and kinetics of migration in drug-treated MDA-MB-231 cells. Cell migration in real time was 
analysed by the xCELLigence RTCA. (A) and (C) show the cell indexes over 12 hours for each drug treatment at 1 µM. (B) and (D), cell 
migration analysis at 6 hr. (E) and (F) Viability was assessed by Cell Titer Blue assay. MDA-MB-231 cells were treated for 72 hours with 
indicated drugs at 1 µM. Data are mean ± S.D, n = 3 (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001 and ****p ≤ 0.0001).
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Chemistry
Based upon the observations above and literature 
precedence, we postulated that a compound containing 
both MNK1/2 and PI3K/mTOR inhibitory activities might 
be very effective against cellular migration. A further aim 
of this work was to synthesise novel hybrid molecules 
based upon 1 and either PP242 or 2 used in this study. 
The desired outcome was the development of a novel, 
single molecular framework incorporating both moieties. 
The hybrid concept covers either permanent or prodrug, 
cleavable dual-action molecules, i) or ii) (Figure 6).
The “type ii)” hybrid compounds (6 and 7) were 
prepared as outlined in Supplementary Scheme 1. 
Compound 6 was prepared via a simple one-pot synthesis 
as detailed in the ESI. Compound 7 was prepared by 
initially converting the carboxylic acid functionality of 
the starting material, 1 [30] into an acid chloride. This 
intermediate then underwent an esterification reaction 
with PP242, leading to the formation of 7 in the presence 
of base. The final products were fully characterised by 
HRMS and 1H NMR. Single crystals of both 6 and 7 were 
isolated from a chloroform solution and the resulting 
X-ray analysis is depicted in Figure 7, which showed the 
expected connectivity i.e. the ester bonds in the products 
[39].
In vitro analysis of hybrid agents in MRC5 cells
Compounds 6 and 7 were screened for activity 
in MRC5 cells by Western blotting (Figure 8A and 
8B) and compared with known kinase inhibitors, PI-
103 and staurosporine. Notably, both 6 and 7 were 
difficult to solubilise in DMSO and this was reflected 
Figure 5: Flow cytometry analysis of the effect of MNKI-19, 191.3 and PP241 both as single agents and in combination 
(5 μM) on cell cycle progression. (A) Representative plots for MDA-MB-231 cells treated for 24 hr with indicated inhibitors at 5 µM 
unless otherwise stated in the data table. (B) Data are mean ± S.D, n = 2. 
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in the Western blot analysis. Compound 6 failed to 
show any noticeable effect on either PI3K or MNK1/2 
signalling output relative to the controls, represented 
by little change in AKT-T308-P or eIF4E-P levels, 
respectively. mTORC1 read-outs, 4E-BP1, S6K T389-P 
and phospho-ribosomal S6 protein also indicated a lack 
of inhibition of mTORC1 signalling. In addition, ULK-
1-P and AMPK-T172-P were unaffected by the inhibitors 
used, indicating that cells had not activated a general 
stress response. When compared to the solvent control, 
compound 7 slightly reduced the level of eIF4E-P when 
tested at the highest concentration (10 µM). mTORC1 
inhibition was observed at the highest concentration, 
reflected by the collapse of the broad 4E-BP1 signal 
into a condensed band and a reduction in ribosomal 
protein S6 phosphorylation. There was a low level of 
cleaved PARP in cells treated with the 1:1 mixture of 1/ 
PP242 and in cells treated with compound 7, suggesting 
that this combination in both forms contributed to cell 
death. The poor solubility of 6 and 7 can be explained in 
part by their physiochemical properties, including high 
molecular high weight (>500), TPSA (>140 A2), log P 
(>5) (Supplementary Table 1, ESI). 
CONCLUSIONS
Using MDA-MB-231 cells, we have determined that 
a synergistic combination of MNK1/2 and PI3K inhibitors 
slowed the rate of cell migration. Additionally, a combination 
of MNK1/2 and mTORC1/2 inhibitors resulted in cell cycle 
arrest and a decrease in cell viability to a greater extent 
in comparison to when the inhibitors were used as single 
agents. This led to the attempted development of novel 
hybrid entities, encapsulating MNK1/2 and PI3K/ mTOR 
inhibitory activities. Although molecular hybridisation 
approaches hold significant promise, they currently face 
considerable challenges as therapeutic modalities [40–48]. 
For example, both 6 and 7 are undoubtedly poorly soluble 
due to their high molecular weight and lipophilicity. 
However, simultaneous MNK1/2 and PI3K/mTOR 
inhibition warrants further investigation as a therapeutic 
option for treating aggressive migratory cancers [49]. 
Figure 6: “Permanent” vs. cleavable hybrid approach.
Figure 7: Crystal structures of hybrid agents. (A) Compound 6 (CCDC 1813013), (B) Compound 7 (CCDC 1813012).
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MATERIALS AND METHODS
Cell culture and cell viability assays
MRC5 human male foetal lung fibroblasts, SV40 
transformed, and MDA-MB-231, human Caucasian 
female breast adenocarcinoma cells were sourced from 
the European Collection of Cell Cultures (ECACC) and 
maintained in Minimal Essential Medium with Glutamax 
and Earl’s salts (MEM, Gibco), supplemented with 10% 
(v/v) foetal bovine serum (FBS, Pan Biotech) at 37° C in 
a humidified atmosphere with 5% CO2. Cell passage was 
performed when cells were 70–80% confluent. Cells were 
first washed with Dubecco’s Phosphate Buffered Saline 
without calcium chloride or magnesium chloride (DPBS, 
Sigma Aldrich) prior to the addition of cell dissociation 
agent, TripLE Select using 1 mLcm-2 (ThermoFisher 
Scientific). Cell viability was measured with the 
CellTiter-Blue reagent (Promega) per the manufacturer’s 
instructions. Cells were plated in clear-bottomed 96-well 
plates at a density of 5000 cells per well. The inhibitors 
were added the following day, and cell viability was 
measured 24 hours later using the Synergy HT Multi-
Detection Reader (BioTek). Relative cell viability at 
a given inhibitor concentration was determined by 
comparing the fluorescence to that of DMSO treated cells.
Cell migration assay
The Oris Universal Cell Migration Assembly kit was 
purchased from AMS Biotechnology (Europe) Ltd and 
the assay was performed according to the manufacturer’s 
instructions. Briefly, a single cell suspension (5 × 104 cells/ 
well/ 100 μL) was loaded into stopper-loaded wells in a 96-
well plate. Cells were incubated in a humidified chamber 
(37° C, 5% CO2) for 4 hours to permit cell attachment. 
To start cell migration, the stoppers were removed, cells 
were washed with sterile PBS and fresh complete medium 
was added. Images were taken at various indicated time 
points using an Optika XDS-2 light microscope, (4x 
objective lens). Data were analyzed with ImageJ software 
(National Institute of Health, Bethesda, MA, USA). Using 
the xCELLigence DP device from Roche Diagnostics real-
time measurements of cell migration on MRC5 cells were 
performed. Cells were seeded at 30,000 per well in CIM-
Plates 16 (Roche Diagnostics) in serum-free medium in 
Figure 8: Characterisation of hybrid agents. (A) and (B) Western blot analysis showing the effect of different concentrations of 
compounds 6 and 7 respectively on various signalling molecules. MRC5 fibroblast cells were incubated with DMSO alone or with the 
indicated concentrations of inhibitors for 24 hours. Cellular lysates were prepared and immunoblotting was performed using 20 µg of total 
lysate protein, as described in the Materials and Methods. 
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the presence or absence of inhibitors. Full growth medium 
was used as a chemo-attractant in the lower chamber. As 
cells pass through the 8 µm pores towards the chemo-
attractant they adhere to the underside of the filter, 
embedded with a gold micro-electrode. This produces 
an electrical impedance signal, which correlates with 
the number of migrating cells. Cell index is an arbitrary 
unit based upon the measured cell-electrode impedance 
derived by the software using the following calculation as 
described in reference [27].
Immunoblotting
Cellular lysates were prepared using lysis buffer 
(20 mM MOPS pH7.4, 100 mM KCl, 1 mM DTT, 1 
mM EDTA, 2 mM benzamidine, 25 mM NaF, 5 µg/mL 
leupeptin, 10 mM chymostatin, 1 µM microcystin LR, 1 
X EDTA-free protease inhibitor cocktail (Roche)). The 
concentration of lysate protein was determined by Bradford 
assay (Bio-Rad). Immunoblotting was performed using the 
Mini-PROTEAN Tetra Cell System (Bio-Rad) with 20 µg 
of lysate protein. The primary antibodies used were β-actin 
(Abcam), cleaved PARP (Cell Signalling Technologies), 
AMPK(phospho-T172; Cell Signalling Technologies), 
eIF4E-(phospho-S209; Abcam), S6K(phospho-T389; 
Cell Signalling Technologies), Phospho-p44/42 MAPK 
(Erk1/2) (Thr202/Tyr204, Cell Signalling Technologies), 
4E-BP1 (Cell Signalling Technologies), p38-MAPK 
(Thr180/Tyr182, Cell Signalling Technologies), Phospho-
Mnk1 (T197/202; Cell Signalling Technologies), 
Phospho-S6 Ribosomal Protein (S240/244, Cell Signalling 
Technologies), eIF4E (Cell Signalling Technologies), 
Phospho-Akt (T308, Abcam), Phospho-ULK1 (S555, Cell 
Signalling Technologies) and Anti-LC3B (Sigma).
Flow cytometry
Cells were seeded at 1 × 105 in 12-well plates and 
allowed to adhere overnight. The cells were treated with 
the indicated concentrations of inhibitors for 24 hours. 
Samples were collected and fixed in 70% ethanol for 1 
hour. For cell cycle analysis, fixed cells were treated with 
10 µg/ml RNAse A for 45 minutes before the addition 
of 50 µg/ml propidium iodide for 15 minutes and then 
analysed by FACs using the Accuri C6 Flow Cytometer.
Chemical synthesis general procedures
All reactions were carried out in air using 
commercial grade starting materials, solvents, and 
reagents. The progress of all reactions was monitored by 
thin layer chromatography (TLC) using commercially 
available glass silica gel plates (60 Å, F254). The 
mobile phase was generally a solvent mixture, and the 
visualization was undertaken using UV light. All NMR 
spectra were measured on a Varian NMR 500 spectrometer 
at 500 MHz (1H). Chemical shifts are quoted in parts 
per million (ppm; % relative to a residual solvent peak 
for 1H). Chromatographic purifications were undertaken 
using an ISCO purification unit, Combi Flash RF 75 PSI, 
using Biotage silica gel columns. LC-MS purity analyses 
were undertaken using a 5 μm C18 110 Å column. The 
synthesis of the hybrid agents is detailed in the ESI. 
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